Corvus Pharmaceuticals, Inc.

NasdaqGM:CRVS 주식 보고서

시가총액: US$322.1m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Corvus Pharmaceuticals 관리

관리 기준 확인 3/4

Corvus Pharmaceuticals' CEO는 Rick Miller, Feb2014 에 임명되었습니다 의 임기는 10.5 년입니다. 총 연간 보상은 $ 1.32M, 8.3% 로 구성됩니다. 8.3% 급여 및 91.7% 보너스(회사 주식 및 옵션 포함). 는 $ 7.24M 가치에 해당하는 회사 주식의 2.82% 직접 소유합니다. 7.24M. 경영진과 이사회의 평균 재임 기간은 각각 4.7 년과 9.2 년입니다.

주요 정보

Rick Miller

최고 경영자

US$1.3m

총 보상

CEO 급여 비율8.3%
CEO 임기10.6yrs
CEO 소유권2.8%
경영진 평균 재임 기간4.8yrs
이사회 평균 재임 기간9.3yrs

최근 관리 업데이트

Recent updates

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Sep 02

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

CEO 보상 분석

Rick Miller 의 보수는 Corvus Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$23m

Mar 31 2024n/an/a

-US$25m

Dec 31 2023US$1mUS$110k

-US$27m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$39m

Mar 31 2023n/an/a

-US$41m

Dec 31 2022US$524kUS$300k

-US$41m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021US$905kUS$300k

-US$43m

Sep 30 2021n/an/a

-US$7m

Jun 30 2021n/an/a

-US$6m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$1mUS$300k

-US$6m

Sep 30 2020n/an/a

-US$44m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$48m

Dec 31 2019US$1mUS$300k

-US$47m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$1mUS$300k

-US$47m

Sep 30 2018n/an/a

-US$48m

Jun 30 2018n/an/a

-US$51m

Mar 31 2018n/an/a

-US$54m

Dec 31 2017US$1mUS$302k

-US$56m

보상 대 시장: Rick 의 총 보상 ($USD 1.32M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 2.45M ).

보상과 수익: 회사가 수익성이 없는 동안 Rick 의 보상이 증가했습니다.

CEO

Rick Miller (73 yo)

10.6yrs

테뉴어

US$1,321,351

보상

Dr. Richard A. Miller, also known as Rick, M.D., serves as Director of BrainScope Company Inc. since September 2023. He is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Offi...

리더십 팀

이름위치테뉴어보상소유권
Richard Miller
Co-Founder10.6yrsUS$1.32m2.82%
$ 9.1m
Peter Thompson
Co-Founder & Independent Directorno dataUS$95.35k데이터 없음
Leiv Lea
Chief Financial Officer9.8yrsUS$660.76k0.45%
$ 1.5m
William Jones
Senior Vice President of Pharmaceutical Development4.8yrsUS$616.26k0.25%
$ 791.9k
James Rosenbaum
Senior Vice President of Research2.2yrs데이터 없음데이터 없음
Jeffrey Arcara
Chief Business Officerless than a year데이터 없음데이터 없음

4.8yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 관리: CRVS 의 관리팀은 경험 ( 4.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Richard Miller
Co-Founder10.7yrsUS$1.32m2.82%
$ 9.1m
Peter Thompson
Co-Founder & Independent Director9.8yrsUS$95.35k데이터 없음
Elisha Gould
Independent Director9.8yrsUS$101.35k데이터 없음
Linda Grais
Independent Director5.7yrsUS$97.35k0.016%
$ 51.5k
Ian T. Clark
Independent Director7.7yrsUS$93.35k데이터 없음
Scott William Morrison
Independent Director8.8yrsUS$109.35k데이터 없음

9.3yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: CRVS 의 이사회는 경험(평균 재직 기간 9.2 년)으로 간주됩니다.